
ERS Genomics and IRBM have announced that they have entered into a non-exclusive CRISPR/Cas9 license agreement, granting IRBM access to …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

